Thursday, June 13, 2024
HomeNewsOne-shot Sputnik Light Shows 70% Potency Against Delta SARS-CoV-2

One-shot Sputnik Light Shows 70% Potency Against Delta SARS-CoV-2

One-shot Sputnik Light vaccine shows 70% potency against Delta variant

The findings of a study of the effectiveness of the one-shot Sputnik Light vaccine against the Delta variant of SARS-CoV-2 were announced recently. The study was carried out by the RDIF and Gamaleya National Research Center of Epidemiology and Microbiology.

The Gamaleya Center has submitted a report reviewing the efficacy of the Sputnik Light vaccine against the Delta variant to the medRxiv, which will be published soon.

According to the report, the Sputnik Light vaccine singly showed 70% effectiveness against COVID-19 caused by the Delta variant during the first 3 months after vaccination. In the case of people aged 60, the vaccine has shown the efficacy of 75%. Sputnik Light has outperformed some 2-shot vaccines, which have revealed a significant drop in efficiency against the Delta variant to below 50% 5 months after vaccination.

Sputnik Light alone has a much higher potency against severe disease and hospitalizations.

The study collated data gathered in Moscow in July 2021 from 28,000 volunteers who took a single shot of Sputnik Light with a control group of 5.6 million people who were not given vaccines.

Sputnik Light as a booster shot

When utilized as a booster, a one-shot vaccination regime of Sputnik Light has various significant benefits, including the comfort of administration, tracking, and a resilient re-vaccination schedule.

The effectiveness of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be comparable to the effectiveness of the Sputnik V vaccine against the Delta variant: more than 94% against hospitalization and more than 83% against infection.

Sputnik Light Vaccine

The Sputnik Light vaccine used recombinant human adenovirus serotype 26. Sputnik Light has been approved in over 15 countries, with a further 30 countries in the process of registration. Sputnik Light will be manufactured in over ten countries by RDIF’s international partners (India, Argentina, China, Mexico, Serbia, South Korea, Turkey, Vietnam, etc.). SII, the world’s largest vaccine producer, is also amongst them.

Real-world vaccination data in many countries have shown that Sputnik Light is both safe and extremely efficient. According to the Ministry of Health of Buenos Aires, Argentina, the vaccine has an efficacy rate of between 78.6 and 83.7% in the old-aged population. During the country’s continuing immunization drive, the Ministry of Health in Paraguay discovered that Sputnik Light was 93.5% efficient.

Because of its safety and effectiveness, the one-shot Sputnik Light vaccine is presently utilized both alone and in combination with vaccines from other manufacturers in various nations.

Combination of Sputnik Light with other vaccines

The heterogeneous boosting strategy was at the core of Sputnik V. This method has been shown to be effective in developing longer-lasting immunization against COVID-19. RDIF formed alliances with other vaccine manufacturers to carry out joint research on the combination of the 1st component of Sputnik V with other vaccines.

Similar studies are presently underway in Argentina, Azerbaijan, Russia, UAE, etc.

Particularly, the RDIF, the Ministry of Health of Argentina, the Ministry of Science of Argentina, and CONICET are carrying out research to assess the immune response and safety of heterogeneous regimes combining Sputnik Light and vaccines manufactured by AstraZeneca, Moderna, and Sinopharm. The study’s prefatory findings validate a high safety profile of combinations, with no severe side effects associated with the vaccine.

Prefatory findings from an Azerbaijan clinical trial combining the AstraZeneca vaccine and Sputnik Light showed that antibodies to the SARS-CoV-2 virus spike protein were elicited in 100% of participants. The combination of the vaccines also has a high safety profile, with no severe side effects or cases of COVID-19 infection following vaccination.

The Delta variant of SARS-CoV-2 is one of the most prevalent and deadly strains, said Denis Logunov, Deputy Director of the Gamaleya Center. The Gamaleya Center’s data analysis exhibited in the article shows that Sputnik Light prevails highly effective months after vaccination. The study’s findings outperformed those of some other vaccines previously published in scientific journals. Due to the vaccine’s one-shot regime, it is a great option for nations with low vaccination rates. This vaccine can also be utilized as a booster shot to sustain subsisting herd immunity.

According to Kirill Dmitriev, CEO, RDIF, the potency outcomes of the one-shot Sputnik Light vaccine against the Delta variant of SARS-CoV-2 undoubtedly outrun several two-shot vaccines. Importantly, the Gamaleya Center data validates that the one-time Sputnik Light vaccine is amongst the best COVID-19 vaccines. Many other studies have authenticated this.


Also Read:

Download Biotecnika App for more Updates on Life Sciences, Job vacancies, CSIR-NET, GATE, and a lot more.

Keywords: One-shot Sputnik Light Vaccine Shows 70% Potency Against Delta Variant



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments

Aarati Bhirwandekar 9967415389 on Amgen Biotech Jobs – Scientist Post Vacancy